Promising Phase I/II results for new ... - Advanced Prostate...

Advanced Prostate Cancer

21,189 members26,458 posts

Promising Phase I/II results for new LU PSMA 617 + NOX66 combo

curious-mind1 profile image
5 Replies

This drug combo is being deployed on Phase 4 patients, and so far they are reporting 70 response rate: snmmi.org/NewsPublications/...

Arthur

Written by
curious-mind1 profile image
curious-mind1
To view profiles and participate in discussions please or .
5 Replies
tango65 profile image
tango65

Very interesting. Thanks for posting.

NPfisherman profile image
NPfisherman

Thanks for posting...as they work on a multimodal attack on PCa, I believe we will see additional positive news....the science is coming....sadly, not fast enough for some...Informative news...

Fish

CantChoose profile image
CantChoose

Australia! Good option for our next trialvacation.

jdm3 profile image
jdm3

It is encouraging to know there are so many combinations being tested - and that some appear to be very promising. Thank you for posting this. Definitely going into my folders.

deedeer profile image
deedeer

Yes thank you for this post, curious-mind1, very interesting. The future looks very promising, here's hoping we can all benefit...... I've added to my 'positive outcomes' research folder

You may also like...

VISION trial results of Lu-177-PSMA-617

ces-positive-result-phase-iii-study-radioligand-therapy-177lu-psma-617-patients-advanced-prostate-ca

New Phase 1b (NON-randomized, dose timing) trial of Lu-177-PSMA-617 + Keytruda at UCSF announced

I know that several patients are looking for a non-randomized trial in the US. This one relies on...

New Trial of Lu-177-PSMA-617 to begin April 30, 2021.

bone scan/CT/MRI. Although it is randomized 1:1, patients in the control group (who will receive an...

EXPANDED ACCESS FOR Lu-PSMA-617

defining which procedures, tests, or drugs that I will be responsible. My PSMA scan is scheduled...

Lu-177-PSMA-617 VISION trial suspended temporarily for new recruiting

suspended. The problem is the very high drop-out rate among those randomized to the control group...